Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Castle Biosciences (CSTL) has 4 years of Non-Current Deffered Revenue data on file, last reported at $986000.0 in Q3 2021.

• Quarterly Non-Current Deffered Revenue fell 13.51% year-over-year to $986000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $986000.0 (down 13.51% YoY) and the FY2020 annual result came in at $1.7 million, changed N/A from the prior year.
• Non-Current Deffered Revenue retreated to $986000.0 in Q3 2021 per CSTL's latest filing, from $995000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $1.7 million in Q4 2020, with the low at $44000.0 in Q4 2018.
• Average Non-Current Deffered Revenue over 4 years is $667521.8, with a median of $941000.0 recorded in 2020.
• Year-over-year, Non-Current Deffered Revenue jumped 1935.5% in 2020 and retreated 13.51% in 2021.
• Castle Biosciences' Non-Current Deffered Revenue stood at $44000.0 in 2018, then increased by 27.29% to $56006.0 in 2019, then surged by 2997.88% to $1.7 million in 2020, then tumbled by 43.17% to $986000.0 in 2021.
• Business Quant data shows CSTL's Non-Current Deffered Revenue at $986000.0 in Q3 2021, $995000.0 in Q1 2021, and $1.7 million in Q4 2020.